following a full submission assessed under the end of life medicine process:
cemiplimab (Libtayo®) is accepted for restricted use within NHSScotland.
Indication under review: In combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥1% of tumour cells) with no EGFR, ALK or ROS1 aberrations, who have:
- locally advanced NSCLC who are not candidates for definitive chemoradiation, or
- metastatic NSCLC
SMC restriction: Treatment with cemiplimab is subject to a stopping rule of a maximum of 36 three-weekly cycles.
Evidence from a double-blind, phase III study demonstrated that cemiplimab plus chemotherapy improved overall survival (OS) compared with placebo plus chemotherapy. Indirect comparisons suggest similar OS and progression-free survival (PFS) compared with pembrolizumab plus chemotherapy, which is a relevant treatment for metastatic NSCLC.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Medicine details
- Medicine name:
- cemiplimab (Libtayo)
- SMC ID:
- SMC2906
- Indication:
In combination with platinum‐based chemotherapy for the first‐line treatment of adult patients with NSCLC expressing PD-L1 (in ≥ 1% of tumour cells), with no EGFR, ALK or ROS1 aberrations, who have:
- locally advanced NSCLC who are not candidates for definitive chemoradiation, or
- metastatic NSCLC
- Pharmaceutical company
- Regeneron Pharmaceuticals Inc
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 09 November 2026